Case File
efta-efta00962027DOJ Data Set 9OtherFrom: Jeffrey Epstein <[email protected]>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00962027
Pages
3
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <[email protected]>
To: "Fenn, Patrick"
Subject: Re: Planning
Date: Sat, 01 Jun 2013 11:25:36 +0000
understood , I think they all should. what happens to the tra payment stream.
On Sat, Jun 1, 2013 at 7:14 AM, Fenn, Patrick <
> wrote:
seperate from the termination clause, we don't have to do all of the outstanding, do we?
PBF: we don't but negative basis will remain to the extent the outstanding remains outstanding.
can each boy opt in or out'/?
PBF: I will look at further but I think each could opt in or out -- effect of the fresh preferred investment would be same
as though the borrowing never happened as to the individual. Anyone of the 3 that does not participate would still have
first tier debt allocation. I'll confirm later. But lack of pro rata participation in new BRH preferred introduces non-tax
issues at BRH.
From: Jeffrey Epstein (mailtoleevacSgmail.com]
Sent: Friday, May 31, 2013 10:39 PM
To: Fenn, Patrick
Subject: Re: Planning
seperate from the termination clause, we don't have to do all of the outstanding, do we? can each boy opt in
or out??
On Fri, May 31, 2013 at 10:03 PM, Fenn, Patrick <
> wrote:
Jeffrey,
I have asked one of my partners to review this but he has not been able to do so as yet. I am sending to you
as a draft with that in mind. I can update over the weekend for his comments. I would suggest running it by
Brian Knudson at EY as well but will wait for your reaction before doing so.
Best regards
Patrick B. Fenn
EFTA00962027
AKIN GUMP STRAUSS HAUER & FELD LLP
One Bryant Park j New Y
NY 10036-6745
USA
Dye
SS
Internal: 31040
Fax:
I
I
I Bio
IRS Circular 230 Notice Requirement: This communication is not given in the form of a covered
opinion, within the meaning of Circular 230 issued by the United States Secretary of the
7:‘-asury. Thus, we are required to inform you that you cannot rely upon any tax advice contained
. this communication for the purpose of avoiding United States federal tax penalties. In
addition, any tax advice contained in this communication may not be used to promote, market or
I recommend a transaction to another party.
information contained in this e-mail message is intended only for the personal and
Jtidential use of the recipient(s) named above. If you have received this communication in
error, please notify us immediately by e-mail, and delete the original message.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to jeeNS®gmail.com, and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Notice Requirement: This communication is not given in the form of a covered
opinion, within the meaning of Circular 230 issued by the United States Secretary of the Treasury.
Thus, we are required to inform you that you cannot rely upon any tax advice contained in this
communication for the purpose of avoiding United States federal tax penalties. In addition, any
tax advice contained in this communication may not be used to promote, market or recommend a
transaction to another party.
The information contained in this e-mail message is intended only for the personal and
confidential use of the recipient(s) named above. If you have received this communication in
error, please notify us immediately by e-mail, and delete the original message.
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
EFTA00962028
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00962029
Technical Artifacts (2)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
mailtoleevacsgmail.comEmail
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.